DeepMed Research

Chinese Academy of Medical Sciences Peking Union Medical College Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Vaginal Microbiome-host Interaction in Mesh Exposure After TVM Surgery

Not yet recruiting

Conditions: Vaginal Microbiome
Graft Versus Host Reaction

First Posted Date: 2021-08-11

Last Posted Date: 2021-09-27

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 50

Registration Number: NCT05000112

Therapeutic Efficiency and Response to 2.0 GBq (55mCi) 177Lu-EB-PSMA in Patients With mCRPC

Early Phase 1

Conditions: Prostate Cancer

Interventions: Drug: 2.0 GBq of 177Lu-EB-PSMA

First Posted Date: 2021-08-09

Last Posted Date: 2022-07-15

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 30

Registration Number: NCT04996602

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

Study of Pomalidomide, Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received Lenalidomide

Phase 4

Conditions: Multiple Myeloma

First Posted Date: 2021-08-04

Last Posted Date: 2021-08-19

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 60

Registration Number: NCT04989140

Locations: 🇨🇳
PekingUMCH, Beijing, Beijing, China

Efficacy and Safety of Bifidobacterium Quadruple Live Tablets in Patients With T2DM and Constipation

Phase 4

Conditions: Type 2 Diabetes Mellitus With Complication

Interventions: Drug: Bifidobacterium, Lactobacillus, Enterococcus and Bacillus Cereus Tablets, Live
Drug: Siliankang simulating tablets

First Posted Date: 2021-07-29

Last Posted Date: 2021-07-29

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 120

Registration Number: NCT04982380

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

A Multi-center Prospective Study of Branch Atheromatous Disease in China

Recruiting

Conditions: Cerebral Infarction
Magnetic Resonance Imaging
Disease

First Posted Date: 2021-07-22

Last Posted Date: 2021-08-04

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 600

Registration Number: NCT04973774

Locations: 🇨🇳
Shengde li, Beijing, Beijing, China

Toripalimab Combined With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Cervical Cancer

Phase 2

Conditions: Cervical Cancer

Interventions: Drug: Toripalimab
Drug: Paclitaxel
Drug: Cisplatin
Drug: Bevacizumab

First Posted Date: 2021-07-22

Last Posted Date: 2021-07-22

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 35

Registration Number: NCT04973904

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

Anlotinib Plus Penpulimab (AK105) for Chemo-refractory Metastatic Colorectal Cancer:ALTER-C003

Phase 2

Conditions: Colorectal Cancer

Interventions: Drug: Anlotinib
Drug: Penpulimab

First Posted Date: 2021-07-21

Last Posted Date: 2022-03-08

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 32

Registration Number: NCT04970914

Locations: 🇨🇳
Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳
China-Japan friendship hospital, Beijing, Beijing, China
🇨🇳
Hebei Petro China Central Hospital, Langfang, Hebei, China

and more 5 locations

An Efficacy Study of Secukinumab In Enthesitis of Psoriatic Arthritis Patients

Phase 1

Conditions: Psoriatic Arthritis

Interventions: Drug: Secukinumab 150 MG
Drug: Secukinumab 300 MG
Drug: Methotrexate

First Posted Date: 2021-07-20

Last Posted Date: 2021-07-20

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 60

Registration Number: NCT04967950

Locations: 🇨🇳
Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, Beijing, China

Data Driven Behavior Intervention and Medical Outcome Evaluation of Patients' Comprehensive Monitoring

Conditions: Metabolic Syndrome
Metabolic Disturbance
Obesity
Metabolic Complication
Infection
Diabetes

First Posted Date: 2021-07-19

Last Posted Date: 2021-07-27

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 1000

Registration Number: NCT04966754

Belimumab In Early Systemic Lupus Erythematosus

Phase 4

Completed

Conditions: Lupus Erythematosus, Systemic

Interventions: Biological: Belimumab
Drug: Standard of care

First Posted Date: 2021-07-09

Last Posted Date: 2022-07-08

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 16

Registration Number: NCT04956484

Locations: 🇨🇳
Peking Union Medical College hospital, Beijing, Dongcheng, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy